Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “bortezomib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 13
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 13 pipeline programs matching "bortezomib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

13 results for “bortezomib” Back to intelligence hub

Search results

  1. Bortezomib

    Hospital Authority, Hong Kong

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  2. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 small molecule active

    1 trial
  3. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial
  4. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial
  5. Bortezomib

    Takeda

    Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial
  6. Bortezomib

    Takeda

    Recurrent Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial
  7. Bortezomib

    Jin Lu, MD

    Systemic Amyloidosis

    phase 2 small molecule active

    1 trial
  8. Vel-FC-4003

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 small molecule active

    1 trial
  9. bortezomib/dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acquired Pure Red Cell Aplasia

    phase 2 small molecule completed

    1 trial
  10. Bortezomib

    ONCOLYTICS BIOTECH INC

    Recurrent Plasma Cell Myeloma

    phase 1 small molecule completed

    1 trial
  11. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Waldenström Macroglobulinemia

    approved small molecule completed

    1 trial
  12. K9520

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    approved small molecule active

    1 trial
  13. SHCZH-2010-CT-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.